Rhode Island is currently home to 499 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Optimizing PrEP Uptake and Adherence Among Male Sex Workers
NCT05736614
Recruiting
"PrEPare for Work" is a randomized controlled trial (RCT) whose goal is to test the efficacy of a behavioral intervention (Short Title: PrEPare for Work) in improving PrEP uptake, adherence, and persistence among male sex workers (MSW)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: The Miriam Hospital, Providence, Rhode Island
Conditions: Prevention
Register for Updates
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
NCT06445946
Recruiting
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factor... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Brown University, Providence, Rhode Island
Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Register for Updates
Intravesical Gentamicin to Prevent Recurrent UTI
NCT06332781
Recruiting
Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI)
Gender:
FEMALE
Ages:
40 years and above
Trial Updated:
05/05/2025
Locations: Women & Infants Hospital, Providence, Rhode Island
Conditions: Recurrent Uti
Register for Updates
Strategies for Improving Remote-based Weight Loss (PATH Trial)
NCT06166225
Recruiting
The purpose of this study is to examine whether the addition of online yoga classes, compared to health and wellness classes, can improve the amount of weight loss produced from an Internet-based weight loss program. All individuals will receive a 12-month, automated Internet-based weight loss program. Following 3 months of of weight loss treatment, individuals will be randomized to also receive yoga classes or health and wellness classes for 9 months. Assessments will occur at baseline, 3, 6, 1... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/05/2025
Locations: The Miriam Hospital's Weight Control and Diabetes Research Center, Providence, Rhode Island
Conditions: Obesity
Register for Updates
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030
Recruiting
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2). Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Colorectal Cancer
Register for Updates
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
NCT04500847
Recruiting
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
05/01/2025
Locations: Memory and Aging Program, Butler Hospital, Providence, Rhode Island
Conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: University Gastroenterology Providence, Providence, Rhode Island
Conditions: Crohn's Disease
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island, Providence, Rhode Island
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Team Science (The Liver Health Study)
NCT06924281
Recruiting
Liver damage from alcohol intake and weight-related behaviors is preventable and treatable only through lifestyle changes. This mixed-methods randomized controlled trial compares standard and enhanced approaches to screening, brief intervention, and referral to treatment/prevention (SBIRT/P) to identify and intervene for metabolism- and alcohol-associated liver disease (MetALD). Our multidisciplinary team aims to show that integrating results of noninvasive liver screening with Fibroscan®, a pai... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/29/2025
Locations: Clinica Esperanza Hope Clinic, Providence, Rhode Island
Conditions: Steatotic Liver Disease of Mixed Origin (MetALD)
Register for Updates
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
NCT05937854
Recruiting
The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated by chance to either active tadalafil or an i... Read More
Gender:
ALL
Ages:
Between 35 years and 89 years
Trial Updated:
04/29/2025
Locations: Providence VA Medical Center, Providence, RI, Providence, Rhode Island
Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Research Site, Providence, Rhode Island
Conditions: Breast Cancer
Register for Updates
Device Global Registry for the IlluminOss Bone Stabilization System
NCT05206981
Recruiting
This is a multi-center, observational patient registry. The primary objective of the study is to collect safety and performance data on the IlluminOss Device when used to provide stabilization and alignment for the treatment of traumatic or impending and pathologic fractures.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/28/2025
Locations: Ortho Rhode Island, Wakefield, Rhode Island
Conditions: Traumatic Fracture, Pathological Fracture
Register for Updates